OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
Daichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e230698-e230698
Open Access | Times Cited: 18
Daichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e230698-e230698
Open Access | Times Cited: 18
Showing 18 citing articles:
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Lung Cancer (2025) Vol. 199, pp. 108079-108079
Closed Access | Times Cited: 1
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Lung Cancer (2025) Vol. 199, pp. 108079-108079
Closed Access | Times Cited: 1
Role of chemotherapeutic drugs in immunomodulation of cancer
Oishi Mukherjee, Sudeshna Rakshit, Geetha Shanmugam, et al.
Current Research in Immunology (2023) Vol. 4, pp. 100068-100068
Open Access | Times Cited: 17
Oishi Mukherjee, Sudeshna Rakshit, Geetha Shanmugam, et al.
Current Research in Immunology (2023) Vol. 4, pp. 100068-100068
Open Access | Times Cited: 17
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e007987-e007987
Open Access | Times Cited: 8
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e007987-e007987
Open Access | Times Cited: 8
Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
T. Nishimura, Hajime Fujimoto, Takumi Fujiwara, et al.
Cancer Medicine (2024) Vol. 13, Iss. 8
Open Access | Times Cited: 5
T. Nishimura, Hajime Fujimoto, Takumi Fujiwara, et al.
Cancer Medicine (2024) Vol. 13, Iss. 8
Open Access | Times Cited: 5
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, et al.
Lung Cancer (2025), pp. 108104-108104
Closed Access
Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, et al.
Lung Cancer (2025), pp. 108104-108104
Closed Access
Chemoimmunotherapy synergism: mechanisms and clinical applications
Rahaman Shaik, Sai Manasa Chittepu, Meghana Tarapatla, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Rahaman Shaik, Sai Manasa Chittepu, Meghana Tarapatla, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Recent advances in immunotherapy for small cell lung cancer
Ziyuan Ren, Shijie Shang, Dawei Chen
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 2
Ziyuan Ren, Shijie Shang, Dawei Chen
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 2
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients
Marie Porte, Adrien Vaudron, Perrine Créquit, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 2, pp. e101-e111.e2
Open Access | Times Cited: 6
Marie Porte, Adrien Vaudron, Perrine Créquit, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 2, pp. e101-e111.e2
Open Access | Times Cited: 6
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)
Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Lung Cancer (2024) Vol. 194, pp. 107896-107896
Closed Access | Times Cited: 1
Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Lung Cancer (2024) Vol. 194, pp. 107896-107896
Closed Access | Times Cited: 1
Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio
Minehiko Inomata, Naoki Takata, Zenta Seto, et al.
In Vivo (2024) Vol. 39, Iss. 1, pp. 467-472
Open Access | Times Cited: 1
Minehiko Inomata, Naoki Takata, Zenta Seto, et al.
In Vivo (2024) Vol. 39, Iss. 1, pp. 467-472
Open Access | Times Cited: 1
Treatment patterns and clinical outcomes in 157 patients with extensive-stage small cell lung cancer: real-world evidence from a single-center retrospective study
Yumin Zheng, Kexin Tan, Aolin Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 1
Yumin Zheng, Kexin Tan, Aolin Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 1
Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study
Kazuhito Misawa, Kageaki Watanabe, Masahiro Seike, et al.
Translational Lung Cancer Research (2023)
Open Access | Times Cited: 1
Kazuhito Misawa, Kageaki Watanabe, Masahiro Seike, et al.
Translational Lung Cancer Research (2023)
Open Access | Times Cited: 1
Immunotherapy for Small Cell Lung Cancer
Yuxuan Ge, Xi Tang
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 08, pp. 320-332
Open Access
Yuxuan Ge, Xi Tang
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 08, pp. 320-332
Open Access
Two Different Responsive Organosilica Nanocarriers to Combine Chemo- and Immunotherapy against Cancer
María Sancho‐Albero, Alessia Lucrezia Fenaroli, Mirco Scaccaglia, et al.
ACS Omega (2024) Vol. 9, Iss. 40, pp. 41225-41235
Open Access
María Sancho‐Albero, Alessia Lucrezia Fenaroli, Mirco Scaccaglia, et al.
ACS Omega (2024) Vol. 9, Iss. 40, pp. 41225-41235
Open Access
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (2024) Vol. 199, pp. 108056-108056
Closed Access
Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (2024) Vol. 199, pp. 108056-108056
Closed Access
Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan
Hidehito Horinouchi, Chia‐Hsien Chang, J.W. Shaw, et al.
Japanese Journal of Clinical Oncology (2024)
Open Access
Hidehito Horinouchi, Chia‐Hsien Chang, J.W. Shaw, et al.
Japanese Journal of Clinical Oncology (2024)
Open Access
Mechanisms of immunotherapy resistance in small cell lung cancer
Yunan Nie, Kurt A. Schalper, Anne C. Chiang
Cancer Drug Resistance (2024)
Open Access
Yunan Nie, Kurt A. Schalper, Anne C. Chiang
Cancer Drug Resistance (2024)
Open Access
